Compare Abeona Therapeutics Inc (ABEO) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.25 (market cap $425.47M), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.61. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | HYG | |
|---|---|---|
Market Cap | $425.47M | — |
Sector | Health | Fixed Income |
52-Week High | $7.46 | $81.32 |
52-Week Low | $4.17 | $78.72 |
Enterprise Value | $280.37M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
HYG trades at $79.61, up 0.16% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent dividends include $0.38 paid in August 2026. News highlights bond market volatility amid oil price swings and inflation data, with HYG facing criticism for underperformance versus peers on expenses and yield.
The outlook is cautious due to high-yield bond risks from rising rates and economic uncertainty. Opportunities exist for income seekers, but downside risks are elevated with support at $79. Investors should weigh HYG's liquidity against weaker metrics compared to alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
